Labcorp Expands Molecular Bioanalytical Laboratory in Greenfield, Indiana

Labcorp has more than 20 years of molecular bioanalytical experience and has supported the development of more than 70 novel therapies to date

Expansion supports the development of advanced cell and gene therapies and the company’s capacity to serve biopharma customers globally
 

BURLINGTON, N.C., Sept. 18, 2024 – Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the expansion of its molecular bioanalytical laboratory in Greenfield, Indiana. The expanded facility will increase Labcorp’s global molecular bioanalytical capacity, enabling the company to help biopharmaceutical customers bring life-saving advanced therapies to patients faster.

"For more than 20 years, Labcorp has been at the forefront of innovation in molecular bioanalysis, leveraging our extensive experience and industry-leading insights to help biopharmaceutical customers advance their most challenging drug development projects," said Megan Bailey, EVP and president, Central Laboratory Services and International for Labcorp. “This expansion underscores our broader strategy of investing in capabilities that reduce lead times for molecular bioanalysis and reinforces our commitment to accelerating the development of advanced therapies, including cell and gene therapies, for patient populations in critical need."

Today, Labcorp operates three global molecular bioanalytical facilities, including those in Greenfield, Indiana, Harrogate, U.K., and Shanghai, China. The expanded Greenfield facility is equipped to support the development and validation of preclinical and clinical molecular bioanalytical assays required for advanced therapies such as cell and gene therapies for oncology, rare disease and other therapeutic areas.

To learn about Labcorp’s molecular bioanalytical services, visit labcorp.com/disciplines/bioanalysis/molecular.
 

About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. Labcorp's more than 67,000 employees serve clients in approximately 100 countries, provided support for 84% of the new drugs and therapeutic products approved in 2023 by the FDA, and performed more than 600 million tests for patients around the world.

Media: Kimbrel Arculeo -- 336-436-8263, [email protected], Investors: Christin O'Donnell -- 336-436-5076, [email protected]